Liquidia Corporation (LQDA) Presents Strategic Overview at Well Fargo's Annual Healthcare Conference 2025 [Yahoo! Finance]
Liquidia Corporation (LQDA)
Last liquidia corporation earnings: 3/11 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Corporation (NASDAQ:LQDA) presented a strategic overview at Well Fargo's Annual Healthcare Conference 2025. The management highlighted a strong early response to Eutrebia, its new treatment for pulmonary conditions. They noted that within eleven weeks of launch, the treatment had over 900 prescriptions and 550 patient starts. The company aims to capture a significant part of the $2 billion oral treprostinil market. Moreover, management also noted that Liquidia Corporation (NASDAQ:LQDA) has contracts with three national players and has achieved a 75% fill rate despite initial challenges. In addition, positive ASCENT trial data supports the effectiveness of higher doses of treprostinil, which is key to Eutrebia. The company expects to reach profitability within three to four quarters, backed by a strong cash balance of over $170 million as of Q2. Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company focused on rare cardiopulmonary diseases such as pulmonary arterial hy
Show less
Read more
Impact Snapshot
Event Time:
LQDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LQDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LQDA alerts
High impacting Liquidia Corporation news events
Weekly update
A roundup of the hottest topics
LQDA
News
- Summers Value Partners Q3 2025 Partner Letter [Seeking Alpha]Seeking Alpha
- Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA's 75% Growth in U.S. Prostacyclin Revenue [Yahoo! Finance]Yahoo! Finance
- Liquidia (NASDAQ:LQDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Liquidia (NASDAQ:LQDA) had its price target raised by analysts at Needham & Company LLC from $36.00 to $52.00. They now have a "buy" rating on the stock.MarketBeat
- Liquidia (NASDAQ:LQDA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $49.00 price target on the stock.MarketBeat
LQDA
Earnings
- 11/3/25 - Beat
LQDA
Sec Filings
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- 12/2/25 - Form 4
- LQDA's page on the SEC website